Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PTGIR | P43119 | 4/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491350 | 1.00 | LIMK1 (0.37) | LIMK1ALDH1A1ADRB2HPGDPTGIR | |
| SCHEMBL4492743 | 0.95 | BACE1 (0.37) | LIMK1ALDH1A1ADRB2HPGDPTGIR | |
| SCHEMBL4492745 | 0.95 | BACE1 (0.37) | LIMK1ALDH1A1ADRB2HPGDPTGIR | |
| SCHEMBL4491548 | 0.93 | LIMK1 (0.37) | LIMK1ALDH1A1RXFP1UTS2RLRRK2 | |
| SCHEMBL4491553 | 0.93 | LIMK1 (0.37) | LIMK1ALDH1A1RXFP1UTS2RLRRK2 | |
| SCHEMBL4493504 | 0.92 | TGM2 (0.44) | LIMK1ALDH1A1HPGDKDM4EPLK1 | |
| SCHEMBL4493501 | 0.92 | TGM2 (0.44) | LIMK1ALDH1A1HPGDKDM4EPLK1 | |
| SCHEMBL4488268 | 0.92 | KDM4E (0.36) | LIMK1ALDH1A1HPGDRXFP1UTS2R | |
| SCHEMBL4488264 | 0.92 | KDM4E (0.36) | LIMK1ALDH1A1HPGDRXFP1UTS2R | |
| SCHEMBL4496690 | 0.91 | LIMK1 (0.36) | LIMK1ALDH1A1RXFP1UTS2RLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | LIMK1 312/4885ALDH1A1 2036/4885ADRB2 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.